HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
News|Articles|October 10, 2025
A "One-Two Punch" to Innovation? The Most Favored Nation Order and Broader US Drug Pricing Reform
Author(s)Rose McNulty
Fact checked by: Maggie L. Shaw
Explore the implications of the Most Favored Nation Order on US drug pricing reform and its potential impact on patient access and innovation.
Advertisement
Advertisement
Drug pricing reform is a complex undertaking, and developments related to the recent Most Favored Nation (MFN) executive order give insight into how the initiative may fit into broader drug pricing reform in the US. This was the basis of discussion at a webinar hosted by MJH Life Sciences® titled “Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform.”
Related to this article
Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
Alice Hall-Partyka, JD, a partner at Crowell & Moring explains the lawsuits challenging CMS' Medicaid rule on pediatric gender care and its legal weak points.
Siva Mohan, MD, explains how drug costs drive silent nonadherence, PA burden, and biosimilar hesitancy, and what payers can do about it.
CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.
New non-CF bronchiectasis in Medicare is tied to high health care use and $8998 PPPM FFS spending; prevalence is highest in older women.
CMS' rule ending Medicaid and CHIP funding for pediatric sex-rejecting procedures is now in effect.
The editor in chief of Evidence-Based Oncology, who was recently named medical director of Precision Medicine for The US Oncology Network, discussed milestones met and those still to be achieved.
Advertisement
Advertisement